Core Viewpoint - Biomerica, Inc. reported a modest decline in net sales for fiscal year 2025, attributed to global tariff uncertainties and a shift in product mix, but achieved significant improvements in operating efficiency and cost management [2][3][5]. Financial Performance - Net sales for fiscal year 2025 were $5.3 million, slightly down from $5.4 million in the previous year [2][6]. - Gross profit decreased to $498,000 from $611,000, reflecting macroeconomic impacts [3][6]. - Operating loss improved to $5.1 million, a 19% year-over-year improvement from $6.4 million [5][6]. - Cash used in operating activities reduced to $3.8 million from $5.3 million, indicating stronger operational discipline [3][8]. - Total operating expenses decreased to $5.6 million from $7.0 million, with significant reductions in selling, general, and administrative expenses as well as research and development costs [4][6]. Strategic Growth Areas - Biomerica is focusing on three key areas for revenue growth, including advancements in its inFoods IBS diagnostic product [7]. - The company submitted a Proprietary Laboratory Analyses (PLA) code application for inFoods IBS, which has received approval, enhancing reimbursement pathways [7][9]. - The company is expanding its product offerings in the MENA region and pursuing insurance reimbursement for new products [9][11]. Product Development and Innovation - The inFoods IBS test has shown statistically significant clinical improvements in patient outcomes, with a new self-collection system introduced for easier access [10][13][16]. - Biomerica achieved EU IVDR certification for its food-intolerance diagnostic tests, supporting future commercialization in Europe [10]. - The company has been granted three new international patents related to its inFoods technology platform [12]. Market Expansion - Biomerica has expanded its footprint in the Middle East with the approval of its Fortel PSA rapid screening test by the UAE Ministry of Health [11]. - The company launched direct-to-consumer availability of inFoods IBS, broadening patient access through telehealth and digital channels [11].